NCT04456777View on ClinicalTrials.gov

Effect of Vortioxetine on Cognitive Symptoms in Patients With Schizophrenia

EARLY_PHASE1UnknownINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

July 1, 2020

Primary Completion Date

July 1, 2022

Study Completion Date

July 1, 2022

Conditions
Cognitive Deficit
Interventions
DRUG

Vortioxetine

vortioxetine will be administreted for 3 months

Trial Locations (1)

10000

RECRUITING

University Hospital Centre Zagreb, Zagreb

Sponsors

Lead Sponsor

Alen Greš
All Listed Sponsors
lead

Alen Greš

OTHER

NCT04456777 - Effect of Vortioxetine on Cognitive Symptoms in Patients With Schizophrenia | Biotech Hunter | Biotech Hunter